Bristol-Myers Squibb Company (NYSE: BMY) is one of the stocks Jim Cramer recently shed light on. When a caller noted that the ...

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

PFIZER said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting higher-than-expected second-quarter earnings on Tuesday.

Share price of Bristol Myers Squibb (BMY) touched a 52-week low of $42.96 on July 31, post its second-quarter earnings ...

One piece of good news: When we expanded our stock screen to include solid companies with a yield of at least 4% rather than ...

Pfizer CEO says drugmakers ‘are all ready to roll up their sleeves and execute’ as president demands more direct-to-consumer ...

This meta-analysis challenges the randomized FRAIL-AF results, but caution is needed when reconciling the discrepant findings ...

PFE posts strong Q2 results with earnings up 30% and revenues up 10% year over year, fueled by rising oncology sales and cost ...

Aug 5 - Pfizer (NYSE:PFE) released its Q2 earnings amid growing investor caution. Pfizer's revenue rose 10% to $14.7 billion, ...

President Trump escalated pressure on the pharmaceutical industry last week by sending letters to 17 major drug companies ...

Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.